TEVA FY 2024 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

FY 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$16.5B+4.4% YoY

Gross Profit

$8.1B48.7% margin

Operating Income

-$303M-1.8% margin

Net Income

-$1.6B-9.9% margin

EPS (Diluted)

$-1.45

Cash Flow

Operating Cash Flow

$1.2B

Free Cash Flow

$749M

Stock-Based Comp.

$123M

Balance Sheet

Total Assets

$39.3B

Total Liabilities

$33.6B

Stockholders' Equity

$5.4B

Cash & Equivalents

$3.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16.5B	$15.8B	+4.4%
Gross Profit	$8.1B	$7.6B	+5.5%
Operating Income	-$303M	$433M	-170.0%
Net Income	-$1.6B	-$559M	-193.2%